CanVirex is a next generation immunotherapeutics company founded as a spin-off from Heidelberg University Hospital and National Center for Tumor Diseases. CanVirex develops viro-immunotherapeutics for treatment of cancer and platform for vaccination against infectious diseases, specifically COVID-19.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business